Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2021										Related Pages
										Return to Main Menu
Table of ContentsExecutive CommentaryExecutive CommentaryTablesTable 1. Tuberculosis Cases, Incidence Rates per 100,000 Population, Deaths, Death Rates per 100,000 Population, and Percent Change: United States, 1953–2021
Table 2. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population by Hispanic Ethnicity and Non-Hispanic Race:1 United States, 1993–2021
Table 3. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population Among U.S.-Born Persons1by Hispanic Ethnicity and Non-Hispanic Race:2 United States, 1993–2021
Table 4. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population Among Non-U.S.–Born Persons1by Hispanic Ethnicity and Non-Hispanic Race: United States, 1993–2021
Table 5. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population by Age Group: United States, 1993–2021
Table 6. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population Among U.S.-Born Persons1 by Age Group: United States, 1993–2021
Table 7. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population Among Non-U.S.–Born Persons1 by Age Group: United States, 1993–2021
Table 8. Tuberculosis Cases and Percentages1 by Birth Decade Cohort Among U.S.-Born Persons:2 United States, 1993–2021
Table 9. Tuberculosis Cases and Percentages1 by Birth Decade Cohort Among Non-U.S.–Born Persons:2 United States, 1993–2021
Table 10. Tuberculosis Cases, Percentages, and Incidence Rates per 100,000 Population by Origin of Birth:1 United States, 1993–2021
Table 11. Tuberculosis Cases and Percentages Among Non-U.S.–Born Persons1 by the Top 30 Countries2 of Birth: United States, 2017–2021
Table 12. 5-Year Tuberculosis Incidence Rates per 100,000 Population in the United States by Country of Birth1, 2017–2021
Table 13. Tuberculosis Percentages Among Non-U.S.–Born Persons1 by Number of Years in the United States Prior to TB Diagnosis, 1993–2021
Table 14. Tuberculosis Cases and Percentages by Case Verification Criterion and Site of Disease: United States, 1993–2021
Table 15. Tuberculosis Cases and Percentages by Drug Resistance and History of Previous TB: United States, 1993–2021
Table 16. Tuberculosis Cases and Percentages Among U.S.-Born Persons1 by Drug Resistance and History of Previous TB Disease: United States, 1993–2021
Table 17. Tuberculosis Cases and Percentages Among Non-U.S.–Born Persons1 by Drug Resistance and History of Previous TB Disease: United States, 1993–2021
Table 18. Percentages of Tuberculosis Cases by Initial Drug Regimen, Method of Administration, and Completion of Therapy (COT): United States, 1993–2021
Table 19. Tuberculosis Cases and Percentages Among Persons with HIV1 Test Results2 and with HIV Coinfection by Age Group:3 United States, 2011–2021
Table 20. Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Was Stopped: United States, 1993–20191
Table 21. Deaths Reported Among Persons with Tuberculosis Disease: United States, 2010–20191
Table 22. Sputum Culture Conversion: United States, 2010–20191
Table 23. Extrapulmonary Tuberculosis Cases and Percentages by Site of Disease: United States, 2010–2021
Table 24. National Tuberculosis Genotyping Surveillance Coverage:1 United States, 2004–2021
Table 25. National Tuberculosis Genotyping Surveillance Coverage:1 United States-Affiliated Reporting Areas,2 2004–2021
Table 26. Genotyped Tuberculosis Cases with Mycobacterium bovis1by Origin of Birth:2United States, 2004–2021
Table 27. Tuberculosis Cases and Incidence Rates per 100,000 Population by Origin of Birth,1Sex, and Age Group: United States, 2021
Table 28. Tuberculosis Risk Factors by Origin of Birth1and Hispanic Ethnicity and Non-Hispanic Race:2United States, 2021
Table 29. Tuberculosis Cases and Percentages by Residence in and Type of Correctional Facilitiy, Ages ≥15 Years: United States, 1993–2021
Table 30. Characteristics of Tuberculosis Cases in GENType Clusters1 by Alert Levels Based on Log-Likelihood Ratio (LLR):2 United States, 2019–2021
Table 31. Tuberculosis Cases and Clusters by Cluster Size:1 United States, 2019–2021
Table 32. Twenty-Five Most Frequently Reported GENTypes1 Among Genotyped Tuberculosis Cases: United States,22019–2021
Table 33. Five Most Frequently Reported GENTypes1 Among Genotyped Tuberculosis Cases: United States-Affiliated Reporting Areas,2 2019–2021
Table 34. Tuberculosis Cases and Incidence Rates per 100,000 Population: Reporting Areas, 2021 and 2020
Table 35. Tuberculosis Cases and Percentages by Age Group: Reporting Areas, 2021
Table 36. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race:1 Reporting Areas, 2021
Table 37. Tuberculosis Cases and Percentages by Origin of Birth:1 Reporting Areas, 2021
Table 38. Tuberculosis Cases and Percentages by Pulmonary and Extrapulmonary Disease: Reporting Areas, 2021
Table 39. Tuberculosis Risk Factors: Reporting Areas, 2021
Table 40. Primary Reason for Tuberculosis Evaluation:1Reporting Areas, 2021
Table 41. Tuberculosis Cases and Percentages by Residence in and Type of Correctional Facilities, Ages ≥15 Years: Reporting Areas, 2021
Table 42. Tuberculosis Cases and Percentages1 by Social Risk Factors, Ages ≥15 Years: Reporting Areas, 2021
Table 43. Tuberculosis Cases and Percentages by Primary Occupation,1 Ages ≥15 Years: Reporting Areas, 2021
Table 44. Tuberculosis Cases and Percentage by Initial Drug Regimen: Reporting Areas, 2021
Table 45. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility Testing (DST) Results by Resistance to Isoniazid or Multidrug Resistance (MDR): Reporting Areas, 2021
Table 46. Tuberculosis Cases and Percentages by HIV Status:1 Reporting Areas, 2021
Table 47. Tuberculosis Genotyping Surveillance Coverage:1 Reporting Areas, 2021
Table 48. Tuberculosis Cases and Percentages by Method of Administration: Reporting Areas, 20191
Table 49. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT):1Reporting Areas, 20192
Table 50. Number and Percentages1of Persons with TB Disease who Completed Therapy Within 1 Year: Reporting Areas, 2015-20192
Table 51. Tuberculosis Cases and Incidence Rates per 100,000 Population: Metropolitan Statistical Areas with ≥500,000 Population, 2021 and 2020
Table 52. Tuberculosis Cases and Percentages Estimated to be Attributed to Recent Transmission and Extensive Recent Transmission: Reporting Areas, 2020–2021
Table 53. Tuberculosis Cases and Percentages Estimated to be Attributed to Recent Transmission and Extensive Recent Transmission: Counties with >5 Percent Estimated Extensive Recent Transmission, 2020–2021
Table 54. Characteristics of Tuberculosis Cases Estimated to be Attributed to Recent Transmission and Extensive Recent Transmission: United States, 2020–2021FiguresFigure 1. Estimated Cases Attributed to Recent Transmission of Tuberculosis, United States, 2020–2021
Figure 2. Estimated Percentage of Extensive Recent Transmission of Tuberculosis in Counties with 10 or More Genotyped Cases, United States, 2020–2021Technical NotesTechnical NotesTuberculosis in the United States Slide SetTuberculosis in the United States Slide Set
Download complete set – (68 slides) [PPT – 8 MB]
PDF Version [PDF – 2 MB]
Slide Set Narrative [PDF – 344 KB]
Archived Surveillance Slide SetsAppendicesAcknowledgements
Appendix A: Tuberculosis Case Definition for Public Health Surveillance
Appendix B: Recommendations for Reporting and Counting Tuberculosis Cases
Appendix C: Genotyping Background Information & GlossaryRelated LinksTable Printing Tips [PDF – 934 KB]
							
					
							Last Reviewed:  November 29, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue